## UNITED STATES PATENT AND TRADEMARK OFFICE

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

FRESENIUS KABI USA, LLC, Petitioner,

V.

NOVO NORDISK A/S, Patent Owner.

Case IPR2022-00657 Patent 8,114,833

PATENT OWNER'S POWER OF ATTORNEY



## PATENT OWNER'S POWER OF ATTORNEY

Patent Owner, Novo Nordisk A/S, hereby appoints the following as its attorneys to transact all business in the United States Patent & Trademark Office associated with the above-captioned *inter partes* review:

<u>Jeffrey J. Oelke</u> having a postal, email, and hand-delivery address of:

Jeffrey J. Oelke, Reg. No. 37,409 Fenwick & West LLP 902 Broadway, Suite 14 New York, New York 10010 Telephone: (212) 430-2600 joelke@fenwick.com

Ryan P. Johnson (*pro hac vice* to be sought), having a postal, email, and hand-delivery address of:

Ryan P. Johnson Fenwick & West LLP 902 Broadway, Suite 14 New York, New York 10010 Telephone: (212) 430-2600 ryan.johnson@fenwick.com

Laura T. Moran (pro hac vice to be sought), having a postal, email, and

hand-delivery address of:

Laura T. Moran Fenwick & West LLP 902 Broadway, Suite 14 New York, New York 10010 Telephone: (212) 430-2600 laura.moran@fenwick.com



IPR2022-00657 Patent 8,114,833

and all other practitioners working in conjunction with the aforementioned attorneys.

The individual signing below has the authority to execute this document on behalf of Novo Nordisk A/S.

[SIGNATURE]

JACOBFOSSAR PETERSEN
[BY]

(ORP. VICE PRESIDENT

21 MARCH 2022 [DATE]

## **CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. §§ 42.6, I hereby certify that the foregoing Patent Owner's Power of Attorney document was served on March 24, 2022, by filing this document through the Patent Trial and Appeal Board End to End System, as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Linnea Cipriano Daryl Wiesen lcipriano@goodwinlaw.com dwiesen@goodwinlaw.com

Date: March 24, 2022 Respectfully submitted,

/Jeffrey J. Oelke/

Jeffrey J. Oelke (Reg. No. 37,409)

Counsel for Novo Nordisk A/S

